芬兰前列腺癌筛查随机研究中的机会性前列腺特异性抗原检测估计
该研究基于芬兰前列腺癌筛查随机研究,回顾性分析对照组与筛查组男性的前列腺特异性抗原(PSA)检测情况。对照组在随访第4、8、12年至少检测一次PSA的比例分别为18.1%、47.7%、62.7%,筛查组分别为69.8%、81.1%、85.2%。筛查组T1c前列腺癌累积发病率为6.1%,对照组为4.5%(RR 1.21,95%CI 1.13-1.30)。作者认为对照组污染可能稀释两组间前列腺癌死亡率的差异。
要点
- 对照组随访第4、8、12年至少一次PSA检测比例分别为18.1%、47.7%、62.7%。
- 筛查组T1c前列腺癌累积发病率为6.1%,对照组为4.5%(RR 1.21,95%CI 1.13-1.30)。
- 作者认为对照组污染可能稀释芬兰筛查试验中两组间前列腺癌死亡率差异。
核心结论
- 对照组中很大比例男性在15年随访期间接受过PSA检测,污染可能稀释芬兰筛查试验中两组间前列腺癌死亡率差异。
研究设计与样本
- 芬兰前列腺癌筛查随机研究(ERSPC最大组成部分)的回顾性分析,48,295名男性随机分入对照组,31,872名分入筛查组,筛查期为1996年至2007年。
主要发现
- 随机分组前1至3年约1.4%男性接受过PSA检测。
- 随访第4、8、12年,对照组至少一次PSA检测比例分别为18.1%、47.7%、62.7%,筛查组分别为69.8%、81.1%、85.2%。
- 筛查组T1c前列腺癌累积发病率为6.1%,对照组为4.5%(RR 1.21,95%CI 1.13-1.30)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Screening for prostate cancer remains controversial, although ERSPC (European Randomized Study of Screening for Prostate Cancer) showed a 21% relative reduction in prostate cancer mortality. The Finnish Randomized Study of Screening for Prostate Cancer, which is the largest component of ERSPC, demonstrated a statistically nonsignificant 16% mortality benefit in a separate analysis. The purpose of this study was to estimate the degree of contamination in the control arm of the Finnish trial. MATERIALS AND METHODS: Altogether 48,295 and 31,872 men were randomized to the control and screening arms, respectively. The screening period was 1996 to 2007. The extent of prostate specific antigen testing was analyzed retrospectively using laboratory databases. The incidence of T1c prostate cancer (impalpable prostate cancer detected by elevated prostate specific antigen) was determined from the national Finnish Cancer Registry. RESULTS: Approximately 1.4% of men had undergone prostate specific antigen testing 1 to 3 years before randomization. By the first 4, 8 and 12 years of followup 18.1%, 47.7% and 62.7% of men in the control arm had undergone prostate specific antigen testing at least once and in the screening arm the proportions were 69.8%, 81.1% and 85.2%, respectively. The cumulative incidence of T1c prostate cancer was 6.1% in the screening arm and 4.5% in the control arm (RR 1.21, 95% CI 1.13-1.30). CONCLUSIONS: A large proportion of men in the control arm had undergone a prostate specific antigen test during the 15-year followup. Contamination is likely to dilute differences in prostate cancer mortality between the arms in the Finnish screening trial.
引用
- Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, et al. Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. J Urol. 2017. PMID: 28104375. doi:10.1016/j.juro.2017.01.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。